NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
Start Date
9/13/2021
Completion Date
6/30/2025
Summary
A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery
Detailed Description
This trial is a single-center, randomized, double-blind placebo-controlled Trial of Nam versus placebo in patients undergoing on-pump cardiac surgery. After screening and enrollment, patients will be stratified according to CKD status (eGFR\<45 ml/min/m2) and surgical site and randomized in a 1:1 manner to receive either Nam 3 grams or placebo on the day of surgery and post-surgical days one and two. The overall trial duration is planned for 42 months, consisting of 39 months of active recruitment and treatment period and three months of follow-up from the last patient enrolled.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Niacinamide
Placebo
Conditions
Locations
Kaiser Permanente San Francisco Medical Center
San Francisco, California 94115
United States